The ambitious prevention study in people with a nearly 100% chance of developing Alzheimer’s disease has failed, and attention will now switch to trial readouts for the next generation of beta-amyloid targeting candidates.
Roche and partner AC Immune’s beta-amyloid targeting drug crenezumab has failed to prevent Alzheimer’s disease in people otherwise almost certain to develop the condition because of a rare genetic mutation.
The results announced on 16 June mark a disappointing but unsurprising end to an ambitious nine-year long study conducted in Colombia in people with the rare inherited form of the
Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.
The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).
The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.
